Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ameliora Wealth Management Ltd.

Key Points

• Ameliora Wealth Management Ltd. reduced its stake in Regeneron Pharmaceuticals by 25.6%, ending up with 2,377 shares worth approximately $1.25 million after selling 820 shares.
• Several large investors increased their positions in Regeneron, with Brighton Jones LLC boosting theirs by 261.8%, indicating significant institutional interest in the company.
• Regeneron's latest earnings report exceeded expectations, posting an EPS of $12.89 and revenue of $3.68 billion, with an anticipated EPS of 35.92 for the current fiscal year.

Ameliora Wealth Management Ltd. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,377 shares of the biopharmaceutical company's stock after selling 820 shares during the period. Ameliora Wealth Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $1,248,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in REGN. Brighton Jones LLC increased its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. NBC Securities Inc. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $78,000. Gateway Investment Advisers LLC boosted its position in Regeneron Pharmaceuticals by 13.9% in the 1st quarter. Gateway Investment Advisers LLC now owns 925 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 113 shares during the last quarter. Sivia Capital Partners LLC boosted its position in Regeneron Pharmaceuticals by 45.2% in the 1st quarter. Sivia Capital Partners LLC now owns 498 shares of the biopharmaceutical company's stock valued at $316,000 after buying an additional 155 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in Regeneron Pharmaceuticals by 17.8% in the 1st quarter. UMB Bank n.a. now owns 1,041 shares of the biopharmaceutical company's stock valued at $660,000 after buying an additional 157 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on REGN shares. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Morgan Stanley reissued an "overweight" rating and issued a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Jefferies Financial Group upped their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday, August 27th. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $585.48 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,024.36. The company's 50-day simple moving average is $572.65 and its 200-day simple moving average is $566.04. The stock has a market capitalization of $62.06 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the company posted $11.56 earnings per share. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.